PFBT
AKBA icon

Parkside Financial Bank & Trust’s Akebia Therapeutics AKBA Stock Holding History

Parkside Financial Bank & Trust’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$524 Buy
+465
New +$554 ﹤0.01% 2589
2025
Q4 		– Sell
-426
Closed -$1.16K – 2685
2025
Q3 		$1.16K Buy
426
+181
+74% +$602 ﹤0.01% 2222
2025
Q2 		$890 Buy
+245
New +$673 ﹤0.01% 2312

Other funds holding AKBA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Parkside Financial Bank & Trust's AKBA Position: Q2 2026 in Review

Parkside Financial Bank & Trust opened a new position in Akebia Therapeutics (AKBA) in Q2 2026: 465 shares worth $524. The stake represents ﹤0.01% of the portfolio and ranks #2589 among its holdings. This is a return to the name: Parkside Financial Bank & Trust previously reported a position in AKBA as recently as Q3 2025.

Parkside Financial Bank & Trust first reported a position in AKBA in Q2 2025 and has held it in 3 quarters since. The position peaked at $1.16K in Q3 2025. 171 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

  • Parkside Financial Bank & Trust held 465 shares of Akebia Therapeutics worth $524 as of Q2 2026.
  • Akebia Therapeutics was a new Parkside Financial Bank & Trust position in Q2 2026.
  • Akebia Therapeutics made up ﹤0.01% of Parkside Financial Bank & Trust's portfolio in Q2 2026, its #2589 holding.
  • Parkside Financial Bank & Trust first reported a position in Akebia Therapeutics in Q2 2025 and has held it in 3 quarters since.
  • Parkside Financial Bank & Trust's Akebia Therapeutics position peaked at $1.16K in Q3 2025.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on Parkside Financial Bank & Trust's 13F filing for Q2 2026, filed 4 Sep 2026.